Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Eubacterium hallii dose-finding study in men with metabolic syndrome
NL-OMON44478Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2014
- Countries
- 1
01
Overview
Phase 2, open-label trial in cardiometabolic risk (CMR) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety, Insulin sensitivity and 1 more. Started Dec 2014; status: active, not recruiting.
02
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on NL-OMON44478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44478.